- Home
- ADCT vs RM Comparison
ADCT vs RM Comparison
Compare ADCT & RM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- RM
- Stock Information
- Founded
- ADCT 2011
- RM 1987
- Country
- ADCT Switzerland
- RM United States
- Employees
- ADCT N/A
- RM N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- RM Finance: Consumer Services
- Sector
- ADCT Health Care
- RM Finance
- Exchange
- ADCT Nasdaq
- RM Nasdaq
- Market Cap
- ADCT 241.0M
- RM 282.1M
- IPO Year
- ADCT 2020
- RM 2012
- Fundamental
- Price
- ADCT $2.97
- RM $26.60
- Analyst Decision
- ADCT Strong Buy
- RM Hold
- Analyst Count
- ADCT 5
- RM 3
- Target Price
- ADCT $7.75
- RM $30.00
- AVG Volume (30 Days)
- ADCT 694.8K
- RM 50.3K
- Earning Date
- ADCT 05-14-2025
- RM 07-30-2025
- Dividend Yield
- ADCT N/A
- RM 4.54%
- EPS Growth
- ADCT N/A
- RM 41.13
- EPS
- ADCT N/A
- RM 3.29
- Revenue
- ADCT $75,817,000.00
- RM $577,647,000.00
- Revenue This Year
- ADCT $9.19
- RM $13.10
- Revenue Next Year
- ADCT $16.27
- RM $9.35
- P/E Ratio
- ADCT N/A
- RM $8.03
- Revenue Growth
- ADCT 10.49
- RM 6.45
- 52 Week Low
- ADCT $1.05
- RM $25.41
- 52 Week High
- ADCT $4.13
- RM $37.52
- Technical
- Relative Strength Index (RSI)
- ADCT 75.65
- RM 33.92
- Support Level
- ADCT $1.83
- RM $26.16
- Resistance Level
- ADCT $2.35
- RM $27.01
- Average True Range (ATR)
- ADCT 0.31
- RM 0.71
- MACD
- ADCT 0.12
- RM -0.15
- Stochastic Oscillator
- ADCT 93.03
- RM 0.00
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.